Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Mizuho Securities Stick to Their Buy Rating for BridgeBio Pharma Inc

Published 06/05/2021, 12:15 PM
Updated 06/05/2021, 12:15 PM


Mizuho Securities analyst Salim Syed maintained a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) Inc on Saturday, setting a price target of $86, which is approximately 48.38% above the present share price of $57.96.

Syed expects BridgeBio Pharma Inc to post earnings per share (EPS) of -$1.18 for the second quarter of 2021.

The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in BridgeBio Pharma, with an average price target of $81.71.
The analysts price targets range from a high of $91 to a low of $71.

In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $462 thousand and a net profit of -$167.5 million. The company's market cap is $8.65 billion.

According to TipRanks.com, Mizuho Securities analyst Salim Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.4% and a 42.86% success rate.

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick (NYSE:MKC), Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.